Literature DB >> 21353612

Molecular mechanism for stabilization of a mutant α-galactosidase A involving M51I amino acid substitution by imino sugars.

Takahiro Tsukimura1, Yasunori Chiba, Kazuki Ohno, Seiji Saito, Youichi Tajima, Hitoshi Sakuraba.   

Abstract

Small molecules including imino sugars are expected to act as chaperones for a mutant α-galactosidase A (GLA), which will be useful for pharmacological chaperone therapy for Fabry disease. However, there is little detailed information about the molecular mechanism. We paid attention to an M51I mutant GLA which had been reported to strongly react to an imino sugar. The predicted structural change caused by this amino acid substitution is very small and located on the surface of the molecule. We produced the mutant enzyme in yeast, and determined its enzymological characteristics. The enzymological parameter values are almost the same as those of the wild-type GLA, although the mutant enzyme is unstable not only under neutral pH conditions but also under acidic ones. Then, we directly examined the effect of imino sugars including 1-deoxygalactonojirimycin and galactostatin bisulfite on the purified mutant enzyme. The imino sugars apparently improved the stability of the mutant enzyme under both neutral and acidic pH conditions. The results of surface plasmon resonance biosensor assaying suggested that the imino sugars retained their binding activity as to the mutant enzyme under both neutral and acidic pH conditions. This information will facilitate improvement of pharmacological chaperone therapy for Fabry disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21353612     DOI: 10.1016/j.ymgme.2011.01.013

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

1.  Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones.

Authors:  Maria Monticelli; Ludovica Liguori; Mariateresa Allocca; Andrea Bosso; Giuseppina Andreotti; Jan Lukas; Maria Chiara Monti; Elva Morretta; Maria Vittoria Cubellis; Bruno Hay Mele
Journal:  Int J Mol Sci       Date:  2022-05-04       Impact factor: 6.208

Review 2.  Fabry disease: experience of screening dialysis patients for Fabry disease.

Authors:  Eiji Kusano; Osamu Saito; Tetsu Akimoto; Yasushi Asano
Journal:  Clin Exp Nephrol       Date:  2013-11-06       Impact factor: 2.801

3.  Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests.

Authors:  Giuseppina Andreotti; Valentina Citro; Agostina De Crescenzo; Pierangelo Orlando; Marco Cammisa; Antonella Correra; Maria Vittoria Cubellis
Journal:  Orphanet J Rare Dis       Date:  2011-10-17       Impact factor: 4.123

4.  Carboxyl-terminal truncations alter the activity of the human α-galactosidase A.

Authors:  Mariam Meghdari; Nicholas Gao; Abass Abdullahi; Erin Stokes; David H Calhoun
Journal:  PLoS One       Date:  2015-02-26       Impact factor: 3.240

5.  High variability of Fabry disease manifestations in an extended Italian family.

Authors:  Giuseppe Cammarata; Pasquale Fatuzzo; Margherita Stefania Rodolico; Paolo Colomba; Luigi Sicurella; Francesco Iemolo; Carmela Zizzo; Riccardo Alessandro; Caterina Bartolotta; Giovanni Duro; Ines Monte
Journal:  Biomed Res Int       Date:  2015-04-22       Impact factor: 3.411

6.  Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease.

Authors:  Valentina Citro; Jorge Peña-García; Helena den-Haan; Horacio Pérez-Sánchez; Rosita Del Prete; Ludovica Liguori; Chiara Cimmaruta; Jan Lukas; Maria Vittoria Cubellis; Giuseppina Andreotti
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

Review 7.  Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations.

Authors:  Ludovica Liguori; Maria Monticelli; Mariateresa Allocca; Bruno Hay Mele; Jan Lukas; Maria Vittoria Cubellis; Giuseppina Andreotti
Journal:  Int J Mol Sci       Date:  2020-01-13       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.